News

Public · Published

TD Cowen maintains PTC Therapeutics at Buy, raises price target to $95 from $90

TD Cowen kept a Buy rating on PTC Therapeutics and raised its price target to $95 from $90, a 5.6% increase. The new target implies 58.4% upside from the Oct 30 close of $59.97.

Published:

Updated:

What happened

TD Cowen kept a Buy rating on PTC Therapeutics and raised its price target to $95 from $90, a 5.6% increase. The new target implies 58.4% upside from the Oct 30 close of $59.97.

Confirmed

Global impact / market context

A higher price target signals that this analyst expects the share price to rise more than previously thought. For a beginner, a price target is an analyst's estimate of where a stock could trade, not a guarantee, so it reflects opinion rather than a confirmed company result.

Analyst inference

Three recent analyst notes on PTC Therapeutics show price targets from $77 to $112, so views differ widely. TD Cowen's $95 sits in the middle of that range, suggesting moderate optimism rather than the most bullish or most cautious stance among those analysts.

Analyst inference

What to watch

  1. Watch whether other analysts change their price targets or ratings on PTC Therapeutics after TD Cowen's move, since the supplied notes range from $77 to $112. Confirmed
  2. Watch for future company updates on drug development or sales, because such updates could give analysts reason to change their price targets, though none are described in the article. Proposed
  3. Watch the gap between the $59.97 close and the $95 target, since a large implied upside suggests the analyst expects a big re-rating that may or may not occur. Analyst inference

Evidence

  • Original source link unavailable